Read by QxMD icon Read


Afsoon Zarei, Mohammad Ebrahim Parsanezhad, Maryam Azizi Kutenaei, Bahia Namavar Jahromi, Parastoo Soheil Esfahani, Pardis Bakhshaei
Objectives: We sought to determine the effects of the delayed start protocol with gonadotropin-releasing hormone (GnRH) antagonists in poor responders undergoing in vitro fertilization (IVF). Methods: This randomized clinical trial was conducted during a 15-month period from April 2014 to July 2015 in clinics in Shiraz, Iran. A total of 42 poor responders with primary infertility were randomly assigned to the controlled ovarian stimulation group utilizing the delayed start protocol (n = 21) or the traditional group (n = 21) using GnRH antagonist, Cetrotide...
November 2018: Oman Medical Journal
Maryam Eftekhar, Ramesh Baradaran Bagheri, Nosrat Neghab, Robabe Hosseinisadat
OBJECTIVE: This study aimed to evaluate the effect of three days of GnRH antagonist pretreatment on the pregnancy outcomes of women with polycystic ovarian syndrome (PCOS) on GnRH antagonist protocols for IVF/ICSI. METHODS: Fifty women with PCOS in the control group received conventional antagonist protocols, starting on day 2 of the cycle. In the pretreatment group (n=38), a GnRH antagonist was administered from day 2 of the menstrual cycle for three days. RESULTS: Controlled ovarian stimulation (COS) duration and gonadotropin dosages were similar in both groups...
September 1, 2018: JBRA Assisted Reproduction
Emaduldin Seyam, Enas Hefzy
OBJECTIVE: The aim of this work was to investigate the value of laparoscopic ovarian drilling (LOD) compared with GnRH antagonist flexible protocol combined with cabergoline (Cb), as a prophylaxis against the re-development of ovarian hyperstimulation syndrome (OHSS) in women with clomiphene citrate-resistant polycystic ovary disease (CCR-PCOD) who had severe OHSS before in a previous ICSI cycle. STUDY DESIGN: It is a prospective controlled study, where 250 CCR-PCOD women (n = 250) with a history of severe OHSS before, had been recruited for the study...
July 2018: Gynecological Endocrinology
Khalid M Salama, Hesham M Abo Ragab, Mohammed F El Sherbiny, Ali A Morsi, Ibrahim I Souidan
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is an important condition with considerable morbidity and a small risk of mortality and most commonly results as an iatrogenic condition following follicular stimulation of the ovaries. We aimed to evaluate safety and efficacy of 3-day cetrotide therapy started on day of oocyte retrieval (Day-0) in women at high-risk for development of ovarian hyperstimulation syndrome (OHSS) after GnRH agonist induction protocol. METHODS: Forty-eight women fulfilling inclusion criteria underwent ultrasound scanning for maximal ovarian diameter (MOD) estimation and ascites grading...
November 13, 2017: BMC Women's Health
Ryutaro Moriyama, Kaho Ueda, Chikaya Deura
GPR120 is a G-protein-coupled receptor that is activated by long-chain fatty acids. In our previous study, GPR120 expression was detected in gonadotrophs of the mouse anterior pituitary gland. It is well known that the function of anterior pituitary cells is largely under the influence of circulating sex steroids. Thus, in the present study, we investigated the modulatory roles of the ovarian hormones, estrogen (E2) and progesterone (P), on the expression levels of GPR120 mRNA in mouse pituitary glands. GPR120 mRNA expression levels in the pituitary gland were increased after ovariectomy or P treatment, and were decreased after the administration of E2...
November 29, 2017: Endocrine Journal
Mohamed M M Kotb, AbdelGany M A Hassan, Ahmed M A AwadAllah
OBJECTIVE: To provide the best available evidence on the role of dehydroepiandrosterone (DHEA) treatment in improving the outcome of in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in women with poor ovarian response (POR). STUDY DESIGN: A randomized controlled trial conducted in Cairo University hospitals and Dar Al-Teb subfertility and assisted conception centre, Giza, Egypt. 140 women undergoing IVF/ICSI with POR according to the Bologna criteria were randomly divided into 2 equal groups...
May 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Weijie Xing, Haiyan Lin, Yu Li, Dongzi Yang, Wenjun Wang, Qingxue Zhang
OBJECTIVE: To determine if the GnRH antagonist protocol is effective in preventing ovarian hyperstimulation syndrome (OHSS) in potentially high responders. METHODS: A total of 660 IVF-ET/ICSI cycles were retrospectively identified. The inclusion criterion was age ≤ 30 years. Cycles were divided into two groups: a GnRHa group and a GnRHant group. In the GnRHa group, the patients received one single injection of 1.0mg-1.3mg Triptorelin in previous mid-luteal phase...
2015: PloS One
Ya-Qin Wang, Jin Luo, Wang-Min Xu, Qin-Zhen Xie, Wen-Jie Yan, Geng-Xiang Wu, Jin Yang
BACKGROUND: Ovarian stimulation in IVF cycle results in luteal supraphysiological steroid concentrations especially for high response patients. The aim of this study was to evaluate the efficacy of ovarian steroid hormone suppression in luteal phase after oocyte retrieval for preventing severe ovarian hyperstimulation syndrome (OHSS) in high-risk patients with embryo cryopreservation. METHODS: 281 patients with high risk of OHSS were enrolled in this study among 4735 infertile women undergoing their first IVF treatment...
2015: Journal of Ovarian Research
Ahmed M Maged, Adel M Nada, Fouad Abohamila, Ahmed T Hashem, Walaa Ai Mostafa, Ahmed R Elzayat
OBJECTIVE: To compare the new delayed start protocol against the conventional gonadotropin (Gn)-releasing hormone antagonist protocol in poor responders (PORs). STUDY DESIGN: A total of 160 women with poor response to previous in vitro fertilization (IVF) cycle were randomized either to start Gn then Cetrotide 0.25 subcutaneously (sc) added when leading follicle (DF) reach >12 mm or Cetrotide 0.25 mg sc started first from day 2 to day 8 then Gn therapy was added and Cetrotide restarted when DF reach >12 mm...
December 2015: Reproductive Sciences
T N L Vuong, H T Phung, M T Ho
STUDY QUESTION: Does luteinizing hormone (LH) supplementation improve live birth rate after in vitro fertilization (IVF) in patients aged ≥35 years receiving a gonadotrophin-releasing hormone (GnRH) antagonist protocol? SUMMARY ANSWER: There was no difference in live birth rate with use of LH during IVF in patients aged ≥35 years undergoing IVF treatment using a GnRH antagonist protocol. WHAT IS KNOWN ALREADY: Use of GnRH analogues as part of a controlled ovarian hyperstimulation protocol during IVF treatment cycles decreases the amount of LH available to developing follicles...
May 2015: Human Reproduction
Ya-Qin Wang, Nan Yu, Wang-Min Xu, Qin-Zhen Xie, Wen-Jie Yan, Geng-Xiang Wu, Jing Yang
The aim of the present pilot study was to assess the feasibility and efficacy of Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome (OHSS), undergoing embryo cryopreservation following superovulation. A total of 135 patients at high risk of OHSS and undergoing embryo cryopreservation were divided into two groups. In the treatment group (n=39), the patients received daily subcutaneous injections of 0.25 mg Cetrotide between days 1 and 5 following ooctye retrieval, and volume expansion and symptomatic treatment were also provided...
December 2014: Experimental and Therapeutic Medicine
M Werling, A Tandler-Schneider, A Siemann, G Stief, H Kentenich
Case Report: A 38-year-old patient newly diagnosed with invasive ductal breast cancer wished to cryoconserve her unfertilised oocytes. Stimulation was started on the 26th day of her menstrual cycle with daily administration of 300 IE hMG s. c. and a GnRH antagonist (cetrorelix 0.25 mg s. c.). The patient additionally received an aromatase inhibitor during the first 5 days of stimulation (letrozole 5 mg p. o.). Induction of ovulation occurred on the 11th day of stimulation with hCG (10 000 IE s...
November 2012: Geburtshilfe und Frauenheilkunde
Rémi Labrecque, Christian Vigneault, Patrick Blondin, Marc-André Sirard
Ovarian stimulation with FSH combined with an appropriate period of FSH withdrawal (coasting) before ovum pick-up now appears to be a successful way to obtain oocytes with high developmental competence in bovine. Recent results showed that extending follicular growth by only 24 hours has a detrimental effect on oocyte quality as shown by the reduced blastocyst formation rate. Although these treatments are initiated during the luteal phase with low LH level, the small LH pulsatility present at that time could potentially impact follicular development as well as oocyte quality...
May 2014: Theriogenology
T E König, L E E van der Houwen, A Overbeek, M L Hendriks, S N Beutler-Beemsterboer, W K H Kuchenbecker, C N M Renckens, R E Bernardus, R Schats, R Homburg, P G A Hompes, C B Lambalk
STUDY QUESTION: Does the addition of exogenous LH to an IVF/ICSI stimulation protocol with recombinant FSH (r-FSH) and a GnRH antagonist improve the ovarian response and pregnancy rates in women of 35 years and older? SUMMARY ANSWER: Supplementation of LH during the second half of the follicular phase has no effect on pregnancy rates, implantation rates or on ovarian response in women of 35 years and older undergoing GnRH antagonist IVF/ICSI cycles. WHAT IS KNOWN ALREADY: In IVF/ICSI stimulation protocols GnRH agonists or antagonists are administered to prevent a premature pituitary LH surge, which can have a detrimental effect on the IVF/ICSI procedure...
October 2013: Human Reproduction
J B Engel, A Schultze-Mosgau, K Diedrich
Three antagonists of gonadotrophin-releasing hormone are currently clinically available. Cetrorelix (Cetrotide) and ganirelix (Orgalutran/Antagon) have been safely used in assisted reproduction since 1999 and 2000 respectively. The structurally similar abarelix (Plenaxis) has been approved for the therapy of advanced androgen sensitive prostate cancer. However, due to the occurrence of allergic reactions, its use is restricted to only a subgroup of patients. These allergic side effects may not be due to abarelix, as the drug itself does not have a strong histamine liberating potential in vitro, but could be attributed to carboxymethylcellulose (CMC), which only Plenaxis, but not Cetrotide or Orgalutran/Antagon contain...
June 2005: Reproductive Biomedicine Online
Marzieh Agha Hosseini, Atossa Mahdavi, Ashraf Aleyasin, Leili Safdarian, Fatemeh Bahmaee
OBJECTIVE: This novel study describes an effective outpatient treatment for ovarian hyperstimulation syndrome (OHSS) that results in rapid normalization of symptoms. STUDY DESIGN: A total of twenty-seven infertile women undergoing assisted reproductive technique with early-onset OHSS were enrolled in this non-randomized clinical trial in an academic infertility center. In all patients, after complete desensitization with long-term protocol ovarian stimulation with gonadotropins was commenced...
November 2012: Gynecological Endocrinology
Haruhiko Kanasaki, Indri N Purwana, Tselmeg Mijiddorj, Aki Oride, Kohji Miyazaki
Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor, PACAP type 1 receptor (PAC1-R) play an important role in the induction of pituitary gonadotropins. In this present study, we examined whether the PAC1-R was involved in the action of gonadotropin-releasing hormone (GnRH) on gonadotropin FSHβ subunit expression. In a static culture, GnRH stimulation significantly increased PAC1-R expression as well as PACAP gene expression in the gonadotroph cell line, LβT2. Stimulation with low frequency GnRH pulses, which preferentially increase FSHβ, increased the expression of both the PAC1-R and the PACAP genes to a greater extent than did high frequency pulses...
April 11, 2011: Regulatory Peptides
F M Bonilla-Musoles, F Raga, J C Castillo, M Sanz, M Dolz, N Osborne
OBJECTIVE: To determine whether treatment of severe ovarian hyperstimulation syndrome (OHSS) with high-dose gonadotropin-releasing hormone (GnRH) antagonist, due to its luteolytic effect, is an effective method of management. METHODS: Six infertile patients who had been scheduled for embryo transfer and developed early-onset severe OHSS with ascites and hemoconcentration were chosen for treatment with 3.0 mg of a GnRH antagonist (Cetrotide; Cetrorelix, Serono, Madrid, Spain)...
2009: Clinical and Experimental Obstetrics & Gynecology
M Cisse, A Maruani, C Bré, P Domart, A-P Jonville-Bera, L Machet
BACKGROUND: Rosacea fulminans is a rare and severe form of rosacea, with acute onset in women between 20 and 40 years. Although the aetiology remains unknown, pregnancy has been reported to be a triggering factor. We report a case of rosacea fulminans occurring at the onset of pregnancy and discuss a possible triggering role of endocrine factors, as well as therapeutic options. CASE REPORT: A 32-year-old woman with no previous history of dermatological disease consulted for rosacea fulminans appearing within the first three weeks of her first pregnancy, which required hormonal stimulation with recombinant FSH (follitropin alpha, Gonal F) and an LHRH inhibitor (cetrorelix, Cetrotide)...
October 2008: Annales de Dermatologie et de Vénéréologie
J H Check, B Katsoff
OBJECTIVE: To determine if ovulation and pregnancy could be achieved in a case of amenorrhea, estrogen deficiency, and markedly elevated serum follicle stimulating hormone (FSH) through reduction of the serum FSH by a gonadotropin releasing hormone antagonist. METHODS: A 37-year-old woman with hypergonadotropic secondary amenorrhea related to two courses of chemotherapy with alkylating agents and abdominal radiation therapy (Hodgkin's disease and breast cancer) was treated with cetrorelix in an attempt to induce ovulation by lowering elevated serum FSH and hopefully restore sensitivity of the few remaining follicles by restoring down-regulated FSH receptors...
2008: Clinical and Experimental Obstetrics & Gynecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"